– Clinical observations from preliminary data at the lowest dose of MGTA-117 in a Phase 1/2 clinical trial indicate target binding, reduction of target cells in bone marrow, rapid drug clearance and a ...

Besides their role in the pathogenesis of AML karyotype aberrations are the most important independent factors determining the prognosis of patients receiving chemotherapy or stem cell transplantation ...

CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem ...

Utrecht, The Netherlands, January 7, 2013 – Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, today announced that it has selected MCLA-117 as lead candidate ...

Acute myeloid leukaemia (AML) is a malignant disorder characterized by abnormal growth and differentiation of haematopoietic stem cells (HSCs), in which immature myeloid precursors (myeloblasts) ...

Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...

CHEYENNE -- The federal government says Wyoming is eligible for more than $117 million in Abandoned Mine Land payments during the current fiscal year. Interior Secretary Ken Salazar announced funding ...

MGTA-117 is designed to target all of these cells, and clinical evidence of depletion in this patient population provides valuable support that MGTA-117 will robustly deplete target cells in the ...

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today reported ...